Placental stem cell populations
4 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of differentiating the placental stem cells. The invention further provides methods of using the placental stem cells in assays and for transplanting.
-
Citations
93 Claims
-
1-52. -52. (canceled)
-
53. An isolated human placental stem cell that is CD34−
- or is SH2+, SH3+ and SH4+, wherein said placental stem cell is isolated from a human post-partum placenta that has been drained of cord blood and perfused to remove residual blood.
- View Dependent Claims (54, 55, 56, 57, 58, 59, 60, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)
- 61. An isolated population of CD34+ placental stem cells, wherein said CD34+ placental stem cells have been isolated from a human postpartum placenta that has been drained of cord blood and perfused to remove residual blood.
-
65. A method of collecting human CD34−
- placental stem cells from post-partum exsanguinated human placenta, said method comprising;
perfusing said placenta with a perfusion solution in an amount and for a time sufficient to collect cells, wherein said placenta has been drained of cord blood and flushed to remove residual blood prior to said perfusing, and wherein said perfusing is performed by passing said perfusion solution into one or both of the umbilical artery and umbilical vein of said placenta; and collecting said perfusion solution from said placenta so that said CD34−
placental stem cells are collected.
- placental stem cells from post-partum exsanguinated human placenta, said method comprising;
-
66. A method of collecting human CD34+ placental stem cells from post-partum exsanguinated human placenta, said method comprising:
-
perfusing said placenta with a perfusion solution in an amount and for a time sufficient to collect cells, wherein said placenta has been drained of cord blood and flushed to remove residual blood prior to said perfusing, and wherein said perfusing is performed by passing said perfusion solution into one or both of the umbilical artery and umbilical vein of said placenta; and collecting said perfusion solution from said placenta so that said CD34+ placental stem cells are collected.
-
-
67. A method of collecting human placental stem cells from postpartum exsanguinated human placenta, said method comprising:
-
perfusing said placenta with a perfusion solution in an amount and for a time sufficient to collect cells, wherein said placenta has been drained of cord blood and flushed to remove residual blood prior to said perfusing, and wherein said perfusing is performed by passing said perfusion solution into one or both of the umbilical artery and umbilical vein of said placenta; and collecting said perfusion solution from said placenta so that said placental stem cells are collected.
-
-
84. An isolated adherent placental stem cell that is:
-
CD200+ and HLA-G+; CD73+, CD105+, and CD200+; CD200+ and OCT-4+; CD73+, CD105+ and HLA-G+; CD73+ and CD105+ and facilitates the formation of one or more embryoid-like bodies in a population of placental cells comprising said stem cell when said population is cultured under conditions that allow the formation of an embryoid-like body;
orOCT-4+ and facilitates the formation of one or more embryoid-like bodies in a population of placental cells comprising the stem cell when said population is cultured under conditions that allow formation of embryoid-like bodies;
or any combination thereof. - View Dependent Claims (85, 86, 87, 88, 89, 90, 91)
-
-
92. An isolated placental stem cell that expresses one or more genes at a detectably higher level than a bone marrow-derived mesenchymal stem cell,
wherein said one or more genes are ACTG2, ADARB1, AMIGO2, ARTS-1, B4GALT6, BCHE, C11orf9, CD200, COL4A1, COL4A2, CPA4, DMD, DSC3, DSG2, ELOVL2, F2L1, FLJ10781, GATA6, GPR126, GPRC5B, ICAM1, IER3, IGFBP7, IL1A, IL6, IL18, KRT18, KRT8, LIPG, LRAP, MATN2, MEST, NFE2L3, NUAK1, PCDH7, PDLIM3, PKP2, RTN1, SERPINB9, ST3GAL6, ST6GALNAC5, SLC12A8, TCF21, TGFB2, VTN, and ZC3H12A, and wherein said bone marrow-derived stem cell has undergone a number of passages in culture that is equivalent to the number of passages said placental stem cell has undergone.
-
93. A population of isolated placental stem cells, wherein a plurality of said stem cells express one or more genes at a detectably higher level than a population of bone marrow-derived mesenchymal stem cells,
wherein said one or more genes are selected from the group consisting of ACTG2, ADARB1, AMIGO2, ARTS-1, B4GALT6, BCHE, C11orf9, CD200, COL4A1, COL4A2, CPA4, DMD, DSC3, DSG2, ELOVL2, F2RL1, FLJ10781, GATA6, GPR126, GPRC5B, ICAM1, IER3, IGFBP7, IL1A, IL6, IL18, KRT18, KRT8, LIPG, LRAP, MATN2, MEST, NFE2L3, NUAK1, PCDH7, PDLIM3, PKP2, RTN1, SERPINB9, ST3GAL6, ST6GALNAC5, SLC12A8, TCF21, TGFB2, VTN, and ZC3H12A, and wherein said bone marrow derived stem cell has undergone a number of passages in culture that is equivalent to the number of passages said placental stem cell has undergone, and wherein said population of bone marrow-derived mesenchymal stem cells has a number of cells equivalent to that in said population of isolated stem cells.
Specification